Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Journal of Surgical Oncology

Volumn 107, Issue 1, 2013, Pages 15-22

  Winter, Jordan M ^a   Yeo, Charles J ^a   Brody, Jonathan R ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

biomarkers; pancreatic cancer; pancreatic ductal adenocarcinoma; predictive markers; prognostic markers

Indexed keywords

3 HYDROXYBUTYRIC ACID; BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 6; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA GROUP C PROTEIN; FANCONI ANEMIA GROUP G PROTEIN; FLICE INHIBITORY PROTEIN; GEMCITABINE; HISTONE H4; LACTIC ACID; MANNOSE BINDING LECTIN 2; MESOTHELIN; MESSENGER RNA; MICRORNA 155; MICRORNA 21; MICRORNA 210; MITOMYCIN; MUCIN 1; MUCIN 2; PROTEIN P53; PROTEIN S 100; SMAD4 PROTEIN; TRANSCRIPTION FACTOR FOSB; TRIMETHYLAMINE OXIDE; TUMOR MARKER; UNINDEXED DRUG;

ACCURACY; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; CANCER SURGERY; CANCER SURVIVAL; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; EARLY DIAGNOSIS; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HAZARD RATIO; HUMAN; IMMUNOASSAY; LEUKOCYTE MIGRATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLOMICS; MICROARRAY ANALYSIS; PANCREAS ADENOCARCINOMA; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SCREENING TEST; SENSITIVITY AND SPECIFICITY; UNIVARIATE ANALYSIS;

CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; DNA, NEOPLASM; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; PROTEOME; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84871298277     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23192     Document Type: Article

References (86)

1. Van Cutsem E, Kohne CH, Hitre E, et al.: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
2. Jover R, Zapater P, Castells A, et al.: The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009; 45: 365-373.
3. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257.
4. Waldman SA, Hyslop T, Schulz S, et al.: Association of GUCY2C expression in lymph nodes with time to recurrence, disease-free survival in pN0 colorectal cancer. JAMA 2009; 301: 745-752.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998; 351: 1451-1467.
6. Perez EA, Romond EH, Suman VJ, et al.: Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011; 29: 3366-3373.
7. Paik S, Tang G, Shak S, et al.: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24: 3726-3734.
8. Chapman PB, Hauschild A, Robert C, et al.: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-2516.
9. Shedden K, Taylor JM, Enkemann SA, et al.: Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008; 14: 822-827.
10. Cheville JC, Karnes RJ, Therneau TM, et al.: Gene panel model predictive of outcome in men at high-risk of systemic progression and death from prostate cancer after radical retropubic prostatectomy. J Clin Oncol 2008; 26: 3930-3936.
11. Glenn J, Steinberg WM, Kurtzman SH, et al.: Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol 1988; 6: 462-468.
12. Pleskow DK, Berger HJ, Gyves J, et al.: Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110: 704-709.
13. Harsha HC, Kandasamy K, Ranganathan P, et al.: A compendium of potential biomarkers of pancreatic cancer. PLoS Med 2009; 6: e1000046.
14. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
15. Narimatsu H, Iwasaki H, Nakayama F, et al.: Lewis and secretor gene dosages affect CA 19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998; 58: 512-518.
16. Koprowski H, Steplewski Z, Mitchell K, et al.: Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-971.
17. Berger AC, Garcia M Jr, Hoffman JP, et al.: Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: A prospective validation by RTOG 9704. J Clin Oncol 2008; 26: 5918-5922.
18. Tempero MA, Uchida E, Takasaki H, et al.: Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47: 5501-5503.
19. Lamerz R,: Role of tumour markers, cytogenetics. Ann Oncol 1999; 10: 145-149.
20. Homma T, Tsuchiya R,: The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA 19-9 and elastase-1 or ultrasonography. Int J Pancreatol 1991; 9: 119-124.
21. Bedi MM, Gandhi MD, Jacob G, et al.: CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: Is there any benefit? Indian J Gastroenterol 2009; 28: 24-27.
22. Singh S, Tang SJ, Sreenarasimhaiah J, et al.: The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci 2011; 56: 2491-2496.
23. Barton JG, Bois JP, Sarr MG, et al.: Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 2009; 13: 2050-2058.
24. Hartwig W, Hackert T, Hinz U, et al.: Pancreatic cancer surgery in the new millennium: Better prediction of outcome. Ann Surg 2011; 254: 311-319.
25. Kondo N, Murakami Y, Uemura K, et al.: Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010; 17: 2321-2329.
26. Marrelli D, Caruso S, Pedrazzani C, et al.: CA 19-9 serum levels in obstructive jaundice: Clinical value in benign and malignant conditions. Am J Surg 2009; 198: 333-339.
27. Forsmark CE, Lambiase L, Vogel SB,: Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994; 9: 731-734.
28. Maithel SK, Maloney S, Winston C, et al.: Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008; 15: 3512-3520.
29. Humphris JL, Chang DK, Johns AL, et al.: The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012.
30. Kinsella TJ, Seo Y, Willis J, et al.: The impact of resection margin status and postoperative CA 19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer. Am J Clin Oncol 2008; 31: 446-453.
31. Ferrone CR, Finkelstein DM, Thayer SP, et al.: Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24: 2897-2902.
32. Abdalla EK, Adam R, Bilchik AJ, et al.: Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006; 13: 1271-1280.
33. Montgomery RC, Hoffman JP, Riley LB, et al.: Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Ann Surg Oncol 1997; 4: 551-556.
34. Turrini O, Schmidt CM, Moreno J, et al.: Very high serum CA 19-9 levels: A contraindication to pancreaticoduodenectomy? J Gastrointest Surg 2009; 13: 1791-1797.
35. Crane CH, Varadhachary GR, Yordy JS, et al.: Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: Correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29: 3037-3043.
36. Mamon HJ, Niedzwiecki D, Hollis D, et al.: A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma: Cancer and leukemia group B (CALGB) 80003. Cancer 2011; 117: 2620-2628.
37. Hammad N, Heilbrun LK, Philip PA, et al.: CA 19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol 2010; 6: 98-105.
38. Maisey NR, Norman AR, Hill A, et al.: CA 19-9 as a prognostic factor in inoperable pancreatic cancer: The implication for clinical trials. Br J Cancer 2005; 93: 740-743.
39. Heinemann V, Schermuly MM, Stieber P, et al.: CA19-9: A pedictor of response in pancreatic cancer treated with gemcitabine and cisplatin. Anticancer Res 1999; 19: 2433-2435.
40. Wong D, Ko AH, Hwang J, et al.: Serum CA 19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas 2008; 37: 269-274.
41. Ziske C, Schlie C, Gorschluter M, et al.: Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 2003; 89: 1413-1417.
42. Haglund C,: Tumour marker antigen CA125 in pancreatic cancer: A comparison with CA 19-9 and CEA. Br J Cancer 1986; 54: 897-901.
43. Benini L, Cavallini G, Zordan D, et al.: A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3: 61-66.
44. Alldinger I, Dittert D, Peiper M, et al.: Gene expression analysis of pancreatic cell lines reveals genes overexpressed in pancreatic cancer. Pancreatology 2005; 5: 370-379.
45. Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al.: Highly expressed genes in pancreatic ductal adenocarcinomas: A comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63: 8614-8622.
46. Missiaglia E, Blaveri E, Terris B, et al.: Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. Int J Cancer 2004; 112: 100-112.
47. Morse DL, Balagurunathan Y, Hostetter G, et al.: Identification of novel pancreatic adenocarcinoma cell-surface targets by gene expression profiling and tissue microarray. Biochem Pharmacol 2010; 80: 748-754.
48. Jones S, Zhang X, Parsons DW, et al.: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
49. Gronborg M, Bunkenborg J, Kristiansen TZ, et al.: Comprehensive proteomic analysis of human pancreatic juice. J Proteome Res 2004; 3: 1042-1055.
50. Hwang TL, Liang Y, Chien KY, et al.: Overexpression and elevated serum levels of phosphoglycerate kinase 1 in pancreatic ductal adenocarcinoma. Proteomics 2006; 6: 2259-2272.
51. Patwa TH, Li C, Poisson LM, et al.: The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis 2009; 30: 2215-2226.
52. Guo J, Wang W, Liao P, et al.: Identification of serum biomarkers for pancreatic adenocarcinoma by proteomic analysis. Cancer Sci 2009; 100: 2292-2301.
53. Rong Y, Jin D, Hou C, et al.: Proteomics analysis of serum protein profiling in pancreatic cancer patients by DIGE: Up-regulation of mannose-binding lectin 2 and myosin light chain kinase 2. BMC Gastroenterol 2010; 10: 68.
54. Xue A, Scarlett CJ, Chung L, et al.: Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 2010; 103: 391-400.
55. Brand RE, Nolen BM, Zeh HJ, et al.: Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011; 17: 805-816.
56. Napoli C, Sperandio N, Lawlor RT, et al.: Urine metabolic signature of pancreatic ductal adenocarcinoma by (1) h nuclear magnetic resonance: Identification, mapping, and evolution. J Proteome Res 2012; 11: 1274-1283.
57. Bathe OF, Shaykhutdinov R, Kopciuk K, et al.: Feasibility of identifying pancreatic cancer based on serum metabolomics. Cancer Epidemiol Biomarkers Prev 2011; 20: 140-147.
58. OuYang D, Xu J, Huang H, et al.: Metabolomic profiling of serum from human pancreatic cancer patients using 1H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol 2011; 165: 148-154.
59. Wang J, Chen J, Chang P, et al.: MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) 2009; 2: 807-813.
60. LaConti JJ, Shivapurkar N, Preet A, et al.: Tissue and serum microRNAs in the Kras(G12D) transgenic animal model and in patients with pancreatic cancer. PLoS ONE 2011; 6: e20687.
61. Shi C, Fukushima N, Abe T, et al.: Sensitive and quantitative detection of KRAS2 gene mutations in pancreatic duct juice differentiates patients with pancreatic cancer from chronic pancreatitis, potential for early detection. Cancer Biol Ther 2008; 7: 353-360.
62. Olsen CC, Schefter TE, Chen H, et al.: Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: Report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol 2009; 32: 115-121.
63. Dabritz J, Preston R, Hanfler J, et al.: K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer. Pancreas 2012; 41: 323-325.
64. Marchese R, Muleti A, Brozzetti S, et al.: Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer. Br J Cancer 2004; 90: 2243.
65. Gray RG, Quirke P, Handley K, et al.: Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J Clin Oncol 2011; 29: 4611-4619.
66. Paik S, Shak S, Tang G, et al.: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
67. Donahue TR, Tran LM, Hill R, et al.: Integrative survival-based molecular profiling of human pancreatic cancer. Clin Cancer Res 2012; 18: 1352-1363.
68. Stratford JK, Bentrem DJ, Anderson JM, et al.: A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. PLoS Med 2010; 7: e1000307.
69. Winter JM, Tang LH, Klimstra DS, et al.: A novel survival-based tissue microarray of pancreatic cancer identifies clinical useful candidate biomarkers. PloS One 2012.
70. Iacobuzio-Donahue CA, Fu B, Yachida S, et al.: DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol 2009; 27: 1806-1813.
71. Winter JM, Tang LH, Klimstra DS, et al.: Failure patterns in resected pancreas adenocarcinoma: Lack of predicted benefit to SMAD4 expression. 2012.(submitted for publication).
72. Demetri GD, von Mehren M, Blanke CD, et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
73. Goggins M, Goggins M, Schutte M, et al.: Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 1996; 56: 5360-5364.
74. Vander Heiden MG, Cantley LC, Thompson CB,: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009; 324: 1029-1033.
75. Jones S, Hruban RH, Kamiyama M, et al.: Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009; 324: 217.
76. Fong PC, Boss DS, Yap TA, et al.: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-134.
77. Farmer H, McCabe N, Lord CJ, et al.: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921.
78. Gallmeier E, Kern SE,: Targeting Fanconi anemia/BRCA2 pathway defects in cancer: The significance of preclinical pharmacogenomic models. Clin Cancer Res 2007; 13: 4-10.
79. Lowery MA, Kelsen DP, Stadler ZK, et al.: An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation: Clinical descriptors, treatment implications, and future directions. Oncologist 2011; 16: 1397-1402.
80. Conroy T, Desseigne F, Ychou M, et al.: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-1825.
81. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al.: Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 2011; 10: 3-8.
82. Von Hoff DD, Stephenson JJ Jr, Rosen P, et al.: Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010; 28: 4877-4883.
83. Perez-Torras S, Garcia-Manteiga J, Mercade E, et al.: Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer. Biochem Pharmacol 2008; 76: 322-329.
84. Richards NG, Rittenhouse DW, Freydin B, et al.: HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients. Ann Surg 2010; 252: 499-505; discussion 505-506.
85. Costantino CL, Witkiewicz AK, Kuwano Y, et al.: The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase. Cancer Res 2009; 69: 4567-4572.
86. Winter JM, Brennan MF, Tang LH, et al.: Survival after resection of pancreatic adenocarcinoma: Results from a single institution over three decades. Ann Surg Oncol 2012; 19: 169-175.